Here are seven updates in orthopedic biologics in the last 90 days:

A new clinic in Honolulu focuses on non-surgical treatments for orthopedic injuries.

One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal.

Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release.

The co-founders of the Stem Cell Institute of America are being sued, accused of marketing stem cell therapy to seniors by falsely claiming that it is an effective treatment for orthopedic conditions such as arthritis and joint pain.

Bioventus has entered an agreement to acquire Misonix for $518 million in a cash-and-stock transaction.

Implant manufacturer Orthofix has launched FiberFUSE Strip, a demineralized bone graft intended to promote bone growth after spine surgery, in the U.S.

Ortho Regenerative Technologies has submitted requested data related to its Ortho-R drug to the FDA after the company paused its clinical trial.

Vivex Biologics launched its Via Mend synthetic bone fillers, a line of bone graft substitutes, the company announced July 15.

Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition.

Durham, N.C.-based Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable, the company said July 13.

Orthopedic device company RTI Surgical partnered with Exactech to develop and supply biologic bone grafts.

Orthopedic surgeon Scott Rodeo, MD, of New York City-based Hospital for Special Surgery received a $50,000 grant from the Orthopaedic Research and Education Foundation to study an injectable knee biologic.

Lawsuits on behalf of a Florida woman and a Delaware man were filed against Aziyo Biologics after they received a tainted FiberCel implant.

Orthopedic device company Arthrex struck a deal with Celularity to distribute biomaterial products for orthopedic surgery, according to a July 1 news release.

The number of patients treated for tuberculosis after undergoing spine surgery with FiberCel, a bone matrix allograft, is growing.

Ortho Regenerative Technologies named Howard Walthall and Tim Cunningham to its board of directors, the company said June 15.

The FDA is ramping up enforcement activities against companies developing unapproved stem cell therapies, particularly for spine and orthopedic indications, according to the Regulatory Affairs Professional Society.

Ortho Regenerative Technologies received a clinical hold letter from the FDA related to its trial for its hybrid implant, Ortho-R, the company said June 4.

Adipose cells, commonly known as fat, could be a useful source of stem cells to promote bone growth in spinal fusion, according to researchers from Johns Hopkins Medicine in Baltimore.